Everyone Thinks Wegovy Is the Moat. It's the Thing the Moat Was Built to Protect.

In a single year, the thing everyone calls Novo Nordisk's unbeatable advantage shrank by a sixth. Its branded obesity volume share slid from about 85% in early 2024 to roughly 70% by the close of the year, as Eli Lilly's tirzepatide ate into the lead.⁶ By the third quarter of 2025, its share of the GLP-1 diabetes market by value had fallen to 48.1% — no longer even a clear majority.⁶ And in March 2026, the patent on the semaglutide molecule itself expired, and generics arrived in India at roughly half the price.⁸ If Wegovy were the moat, the moat would be visibly draining. So why isn't the company?

The popular story is that Novo Nordisk is protected by its blockbuster drug and the patents around it. That story has the causation exactly backwards. The drug is not the moat. The drug is the thing the moat was built to protect — and the moat itself is older, stranger, and far harder to copy than any molecule.

The patent everyone points to is already cracking

Start with what's eroding, because it clears the ground. The semaglutide compound patent (US 8,536,122) expired in March 2026.⁷ A separate primary US compound patent runs to December 2031 through term adjustment and extension, and Novo has stacked more than twenty patents on Ozempic — most of them covering the injection device, expiring into the late 2030s.⁷ Read that carefully: the late-decade protection is largely on the pen, not the molecule. The molecule is the asset; the pen is the wrapper. Globally, the wall has holes — India is already selling generic semaglutide at roughly half price, forcing Novo into different pricing strategies in different regions.⁸ Patents are a fixed-length lease on a monopoly, and the clock on the most important one has run out. A moat made of expiry dates isn't a moat. It's a countdown.

An owner with 28% of the company and 77% of the votes

Here is the load-bearing wall. Most people assume the Novo Nordisk Foundation owns the company outright. It doesn't. As of November 2024, the Foundation's investment arm, Novo Holdings, held just 28.05% of the share capital — a minority — while controlling 77.28% of the votes.³ The mechanism is a two-tier share structure: A shares, held entirely by Novo Holdings, carry 100 votes each; ordinary B shares carry 10.³ That gap between economic ownership and voting control is the whole point. It means activist investors can buy all the B shares they like and still never reach the wheel.

And the structure is welded shut. The Foundation's Articles of Association legally forbid Novo Holdings from ever divesting its A shares for as long as the Foundation exists, and require the board to block any capital increase that would let the Foundation lose its voting majority.⁴ The differentiated voting rights themselves cannot be revoked without violating those Articles, which are approved by the Danish Foundation Authority.³ This isn't a corporate preference that a bad quarter could change. It is a structural commitment to permanence, immune to the quarterly capital-markets pressure that forces most public companies to manage to the next earnings call. While rivals optimize for buybacks, Novo can pour money into a factory that won't pay off for years — because no one can vote the long view out of the building.

Why a Danish town is harder to copy than a chemical

Permanence is only valuable if you do something with the time it buys. Novo spends it on capacity. The company committed more than DKK 42 billion — roughly $6 billion — in November 2023 to expand manufacturing at Kalundborg, primarily for active-ingredient capacity, with construction phased from late 2025 through 2029.⁵ That sits inside roughly $9 billion of planned 2025 capex and nearly $18 billion of total manufacturing investment in 2024.⁵ These are bets a company gets to make only when no one can demand the cash back next quarter.

And the bet matters because the binding constraint in this market is not invention — it is supply. Novo's own SEC filings concede 'periodic supply constraints and related drug shortage notifications across a number of products and geographies' as a direct result of demand outrunning capacity.¹² A molecule can be reverse-engineered the day its patent lapses. A sterile, regulator-qualified, multi-billion-dollar peptide manufacturing complex cannot be reverse-engineered at all — it has to be built, validated, and inspected, and that takes years even with the money in hand. So a generic maker in India can copy the chemistry overnight and still be unable to make it at the scale a global obesity market demands. The molecule is free now. The factory that fills the pens is not.

Doesn't the structure itself make it dangerously brittle?

The honest objection cuts the other way: a controlling owner with 77% of the votes and almost no skin in the equity is a governance hazard, not a moat. And in November 2025 that hazard went live. The Foundation used its voting power to effectively oust the board chair and independent directors, installing a former CEO in the dual role of Foundation chairman and company board chair — a concentration of control that drew formal protests from minority shareholders.¹⁰ If the owner can rewrite the board overnight on a minority economic stake, the same immunity-from-short-termism that funds the factory can also override outside scrutiny. The same wall that keeps activists out keeps accountability out too. That is real, and it is the genuine cost of this design.

But notice it does not dissolve the thesis — it sharpens it. The market is not a one-horse race; Novo's own 20-F names itself and Eli Lilly as the two most significant players and pointedly declines to call either dominant.² Its total global diabetes value share stood at 34.1% in mid-2024¹¹ and had slipped to 31.6% by Q3 2025.⁶ So the product positions are genuinely contested. What is not contested is the structure underneath them. A rival can out-research Novo on a given drug — Lilly did. A rival cannot acquire a foundation chartered in 1926, a vote structure that cannot legally be unwound, or a Kalundborg that has been continuously built out since 1969.¹³⁹ The governance risk is the price of admission for the only advantage that survives the patent cliff.

Strip away Wegovy entirely and ask what remains. A revenue base of DKK 290 billion in 2024, still anchored by an insulin franchise older than the company's name.¹ An owner that, by its own charter, can never sell and can never be outvoted.⁴ A manufacturing complex being built out through 2029 that no challenger can replicate in time to matter.⁵ The blockbuster is what the world sees, the way you see the castle before you see the water around it. But castles get stormed. Moats are what decide whether the next castle gets built. Novo Nordisk's real protection was never the drug everyone is racing to copy. It was the 1926 decision that no one would ever be allowed to sell the company out from under the next drug — and a town in Denmark you can't build twice.